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Abstract: The accumulation of perturbations in signalling pathways resulting in an apoptosis-
insensitive phenotype is largely responsible for the desperate prognosis of patients with pancreatic
ductal adenocarcinoma (PDAC). Accumulating evidence suggests that the death receptors TRAIL-R1
and TRAIL-R2 play important roles in PDAC biology by acting as either tumour suppressors through
induction of cell death or tumour promoters through induction of pro-inflammatory signalling,
invasion and metastasis. TRAIL-R2 can also associate with nuclear proteins and alter the maturation
of micro RNAs (miRs). By genome-wide miR profiling and quantitative PCR analyses we now
demonstrate that knockdown of TRAIL-R1 in PDAC cells decreased the level of mature miR-370
and led to an increased abundance of the type II receptor for transforming growth factor β (TGFβ).
Transfection of cells with an artificial miR-370-3p decreased the levels of TGFβ-RII. We further
show that transient expression of the miR-370 mimic decreased TGFβ1-induced expression of
SERPINE1 encoding plasminogen activator-inhibitor 1 and partially relieved TGFβ1-induced growth
inhibition. Moreover, stable TRAIL-R1 knockdown in Colo357 cells increased TGFβ1-induced
SERPINE1 expression and this effect was partially reversed by transient expression of the miR-370
mimic. Finally, after transient knockdown of TRAIL-R1 in Panc1 cells there was a tendency towards
enhanced activation of Smad2 and JNK1/2 signalling by exogenous TGFβ1. Taken together, our study
reveals that TRAIL-R1 through regulation of miR-370 can decrease the sensitivity of PDAC cells to
TGFβ and therefore represents a potential tumour suppressor in late-stage PDAC.
Keywords: TRAIL; TRAIL-receptor 1; TGFβ; TGFβ receptor II; microRNA; signalling; pancreatic
ductal adenocarcinoma
1. Introduction
The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumour
necrosis factor (TNF)-family of ligands [1]. Once bound to its receptors, signalling cascades are initiated
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leading to apoptosis on the one hand and inflammation, proliferation, or migration on the other
hand [2]. TRAIL can bind to five different receptors. The membrane-bound receptors TRAIL-receptor 1
(TRAIL-R1, DR4) [3], -2 (TRAIL-R2, DR5, TRICK2, Killer) [4,5], -3 (TRAIL-R3, DcR1) [6], -4 (TRAIL-R4,
TRID, DcR2) [7,8] and the soluble receptor osteoprotegerin (OPG) [9,10]. Since TRAIL preferentially
kills tumour cells while sparing normal healthy cells, TRAIL and agonistic anti-TRAIL-R1 and
TRAIL-R2 antibodies were developed for treatment of different malignancies [11–13]. However,
soon thereafter it has been recognized that many tumour cells are resistant to TRAIL-induced
apoptosis, the fact explaining the disappointing results from clinical trials [13]. In addition to initiating
programmed cell death, TRAIL is also able to promote tumour progression by enforcing inflammation
as well as invasion and proliferation of cells [14–18]. These pathways are activated preferentially in
cells that are resistant against TRAIL-induced apoptosis.
In addition to the aforementioned functions, in cancer cells TRAIL receptors were also found to
be localized in the cytoplasm and in the nucleus [19]. Nuclear localization of TRAIL receptors was
demonstrated in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, mammary carcinoma,
hepatocellular carcinoma and melanoma [20–23]. Recently, it has been shown that nuclear TRAIL-R2
interacts with components of the microprocessor complex, thereby inhibiting the maturation of the
microRNA (miR) let-7. This resulted in an increased proliferation rate and enhanced invasion and
migration in vitro and in reduced pancreatic tumour growth and breast cancer metastasis into the
bone as demonstrated by use of a mouse xenotransplantation model [20,24].
MiRs are small RNA molecules involved in the posttranscriptional regulation of genes,
by degrading mRNAs or inhibiting translation [25]. It is assumed that there are 500–1500 miRs in the
human genome and that 20–30% of all human genes can be regulated by miRs [26]. Since one particular
miR is able to target many different mRNAs, changes in its expression levels may result in a complex
network of posttranscriptional gene regulation [27]. Genes encoding miRs are transcribed by RNA
polymerase II. Still in the nucleus the so called pri-miR is processed by the microprocessor complex
into the precursor (pre-) miR which is 60 to 70 nucleotides long and has a hairpin structure [28].
The main components of the microprocessor complex are Drosha (an RNase III) and DiGeorge
syndrome critical region 8 (DGCR8). Several additional proteins associate with the complex and
can regulate the maturation of the miR [29]. Once exported to the cytoplasm the pre-miR is cleaved
by another RNase III (Dicer) into the mature double-stranded miR [30]. After degradation of one
strand, the remaining one is incorporated into the RNA-induced silencing complex (RISC) which
is the executive part for posttranscriptional gene regulation [31]. Certain expression patterns of
miRs are associated with proliferation, apoptosis or tumour development [32]. In tumour cells the
expression of miRs is often altered and miRs have the capacity to act as either an oncogene or a tumour
suppressor [33]. Being located in a tumour-associated region on chromosome 14, miR-370 has been
linked to tumour pathogenesis [34,35]. Particularly, the miR-370-3p form was described as a tumour
suppressor miR due to its low expression in cancers [36,37]. In contrast, other studies report that
overexpression of miR-370-3p enhanced tumour progression [38,39].
With a median survival of less than one year after diagnosis, PDAC ranks fourth among
tumour-associated death rates [40]. The poor prognosis is due to the fact that most patients already
have acquired metastases when diagnosed with this tumour and that the tumour cells have become
apoptosis-resistant and refractory to standard chemotherapy [41]. Interestingly, the signalling pathway
of transforming growth factor β (TGFβ) is often inactivated in the tumour cells and the genes for
the TGFβ type I receptor (TGFβ-RI/ALK5), TGFBR1 and the type II receptor (TGFβ-RII), TGFBR2,
are selective targets of genetic inactivation in pancreatic cancers [42]. In addition, the mRNAs encoding
TGFβ-RII and TGFβ-RI/ALK5 are directly targeted by several miRs. For TGFβ-RII these include
the miR-302/367 cluster, miR-372, miR-520/373, miR-17-92 cluster, miR-15, miR-16 reviewed in
Reference [43] and miR-370-3p [44]. Since these miRs are capable of inhibiting TGFβ receptor expression
and the receptor levels correlate with TGFβ responsiveness, these miRs control the threshold for
signalling initiation in response to TGFβ [43].
Cancers 2018, 10, 399 3 of 16
Here, we demonstrate that knockdown of TRAIL-R1 in PDAC cells results in decreased amounts
of mature miR-370-3p associated with higher expression of TGFβ-RII and enhanced TGF-β target gene
expression and growth inhibition.
2. Results
2.1. TRAIL-R1 Regulates the Expression of miR-370
To analyse the possible impact of TRAIL-R1 on the expression of miRNAs, we performed
genome-wide miR-profiling in Panc1 cells with and without knockdown of TRAIL-R1. Interestingly,
miR-370 was among the most strongly downregulated miRs in response to TRAIL-R1 depletion
(Figure S1). To verify the array data, we again transfected the Panc1 cells with siRNA against TRAIL-R1
and determined the levels of the mature miR-370-3p by quantitative real-time PCR (qPCR) analysis.
As shown in Figure 1A, downregulation of TRAIL-R1 but not TRAIL-R2 (Figure S2), resulted in
significantly reduced levels of miR-370-3p. In an attempt to elucidate the underlying mechanism,
we first asked whether TRAIL impacts miR-370 expression. Therefore, control siRNA-transfected
Panc1 cells were treated with either recombinant TRAIL or a neutralizing antibody against TRAIL
(anti-TRAIL). The abundance of miR-370-3p was not affected by treatment with TRAIL (Figure 1B) as
no significant changes in expression of mature miR-370 was observed. However, antibody-mediated
deprivation of endogenous TRAIL reduced miR-370 levels significantly albeit slightly. These results
suggest that mature miR-370-3p is positively regulated by TRAIL-R1 in a manner independent of rec.
human TRAIL ligand.
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(TRAIL-R1) decreases levels of mature miR-370-3p but not of pri-miR-370. (A) Quantitative PCR 
analyses detecting changes in the levels of mature miR-370-3p in Panc1 cells transfected for 40 h with 
a control-siRNA (ctrl.-si) or siRNA against TRAIL-R1 (TRAIL-R1-si). (B) Panc1 cells transfected with 
ctrl.-si were stimulated with anti-TRAIL (10 µg/mL), TRAIL (10 ng/mL) or left untreated. Levels of 
mature miR-370-3p were quantified by qPCR. (C,D) QPCR analyses of pri-miR-370 levels in Panc1 
cells transiently transfected with ctrl.-si or TRAIL-R1-si (C) or in ctrl.-si transfected cells with and 
without treatment with TRAIL (10 ng/mL) or anti-TRAIL (1 µg/mL) (D). Shown are the mean ± SD of 
Figure 1. Downregulation of tumour necrosis factor-related apoptosis-inducing ligand-receptor 1
(TRAIL-R1) decreases levels of mature miR-370-3p but not of pri-miR-370. (A) Quantitative PCR
analyses detecting changes in the levels of mature miR-370-3p in Panc1 cells transfected for 40 h with
a control-siRNA (ctrl.-si) or siRNA against TRAIL-R1 (TRAIL-R1-si). (B) Panc1 cells transfected with
ctrl.-si were stimulated with anti-TRAIL (10 µg/mL), TRAIL (10 ng/mL) or left untreated. Levels of
mature miR-370-3p were quantified by qPCR. (C,D) QPCR analyses of pri-miR-370 levels in Panc1 cells
transiently transfected with ctrl.-si or TRAIL-R1-si (C) or in ctrl.-si transfected cells with and without
treatment with TRAIL (10 ng/mL) or anti-TRAIL (1 µg/mL) (D). Shown are the mean ± SD of five
biological replicates (n = 5), with each one analysed in technical duplicates. The asterisks (*) indicate
significance (p < 0.05); n.s.: not significant.
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Next, we addressed the question whether TRAIL-R1 regulates miR-370-3p expression at the
transcriptional level. For this purpose, we compared the levels of pri-miR-370 in cells with and
without knockdown of TRAIL-R1 using qPCR. Although the levels of pri-miR-370 appeared reduced,
differences missed statistical significance (Figure 1C). Likewise, neither treatment with anti-TRAIL nor
with recombinant TRAIL affected the abundance of pri-miR-370 relative to control siRNA (Figure 1D).
These results suggest that neither TRAIL-R1 nor TRAIL (in its exogenous or endogenous form) affects
miR-370-3p expression at the transcriptional level.
2.2. MiR-370-3p Negatively Controls TGFβ-RII in PDAC Cells
Although the regulation of TGFβ-RII by miR-370-3p has been shown in gastric carcinoma [44],
data on pancreatic carcinoma are not available so far. To examine if TGFβ-RII is subject to regulation by
miR-370-3p in PDAC-derived cells, we transfected Panc1 cells with an artificial miR-370-3p (miR-370-3p
mimic) and performed Western blot analysis of TGFβ-RII. As shown in Figure 2, abundance of
TGFβ-RII was decreased in miR-370-3p mimic transfected cells relative to control cells at 48 and
72 h after the start of transfection. This indicates that expression of TGFβ-RII protein is inhibited
by miR-370-3p.
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Figure 2. Ectopic expression of miRNA-370-3 i c lls ecreases the abundance of TGFβ-RII.
Panc1 ells wer transfected with 50 nM of an artifici l i -3p ( iRNA-370-3p mimic) for the
indicated periods of time. The levels of T F alysed by Western blotting in whole cell
lysates. Detection of β-actin served as a loadi graph underneath the blot shows results
from densitometric quantification of band intensities from three indep ndent experiments (mean ± SD,
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2.3. TRAIL-R1 Knockdown Increases the Abundance of TGFβ-RII
Since TGFβ-RII is a target of miR-370 (Figure 2) and knockdown of TRAIL-R1 decreases the cellular
levels of miR-370 (Figure 1), we hypothesized that TRAIL-R1 might impact the levels of TGFβ-RII
in PDAC cells. To validate this hypo esis, we downr gulated the expression of TRAIL-R1 in two
PDAC cell lines and a alyse the ev ls of TGFβ-RII by Western blot. As demonstrated in Figure 3A,
inhibition of TRAIL-R1 expression via siRNA in Panc1 cells was associated with considerably increased
levels of TGFβ-RII. Similar re ults were obtained with Colo357 cells, which were either transiently
transfected with the same siRNA sequences or cells stably transduced with a short-hairpin-RNA
(shRNA, sequence different from that of the siRNA) against TRAIL-R1 (Figure S3). This confirms the
presence of a functional axis of TRAIL-R1, miR-370 and TGFβ-RII.
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To examine a possible ligand dependency of this novel TRAIL-R1 function, Panc1 cells were either
stimulated with TRAIL or incubated with anti-TRAIL (Figure 3B). Interestingly, the abundance of
TGFβ-RII remained unchanged after incubation with TRAIL or anti-TRAIL. We thus conclude that
TRAIL-R1 functions independently of its ligand TRAIL in the regulation of TGFβ-RII.
2.4. Knockdown of TRAIL-R1 Enhances Activation of Smad and Non-Smad Pathways after TGFβ Stimulation
As TGFβ-RII is indispensable for TGFβ signalling, we addressed the question whether an increase
in abundance of this protein after TRAIL-R1 knockdown was associated with enhanced TGFβ
signalling activity. This was studied by measuring C-terminal phosphorylation of Smad2 (p-Smad2C),
a marker for activation of the canonical TGFβ/Smad signalling pathway as well as by assessing the
phosphorylation state of JNK1/2 as indicators of non-Smad signalling. We depleted Panc1 cells of
TRAIL-R1 by siRNA transfection and 48 h later treated the cells with TGFβ1. As shown in Figure 3,
knockdown of TRAIL-R1 led to a strong increase in the levels of TGFβ-RII (Figure 4A, lane 2 vs. 1
and lane 4 vs. 3) and this increase was not affected by treatment with TGFβ1 (Figure 4A, lane 4 vs. 2).
Whereas non-stimulated transfectants failed to exhibit detectable levels of p-Smad2C, stimulation with
TGFβ1 increased the abundance of p-Smad2C and this increase tended to be stronger in TRAIL-R1
knockdown cells compared with control cells (Figure 4A, lane 4 vs. 3, statistical significance tightly
missed in a series of three independent experiments). Neither TGFβ1 stimulation nor depletion of
TRAIL-R1 resulted in alterations of the non-phosphorylated forms of Smad2 and Smad3 (Figure 4A).
These results suggest the possibility that TRAIL-R1 can inhibit Smad activation which would be
consistent with inhibition of TGFβ-RII, as this receptor is crucial for Smad activation by TGFβ1.
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Figure 4. Knockdown of TRAIL-R1 might increase the activation of Smad2 and JNK. Panc1 cells have
been transfected with control siRNA (ctrl.-siRNA) or siRNA against TRAIL-R1 (TRAIL-R1-siRNA) for
72 h prior to treatment with TGFβ1 (0.2 ng/mL) for 50 min. Western blot analysis of (A) p-Smad2C
and (B) p-JNK. Detection of β-actin served as control for equal loading. In (A) in the Smad2/3 panel,
the upper band represents Smad2. The blots in (A,B) are representative of three independent experiments
all yielding, albeit to a varying extent, an induction of p-Smad2C and p-JNK levels, respectively,
in TRAIL-R1-siRNA over ctrl.-siRNA transfected cells. (C) Densitometry-based quantification of the
p-Smad2 bands shown in (A). (D) Densitometry-based quantification of the p-JNK bands shown in (B).
We also analysed the non-phosphorylated and phosphorylated forms—the ratio of which reflects
the activation state—of the mitogen-activated protein kinase JNK1/2. Depletion of TRAIL-R1 in Panc1
cells was associated with a tendency towards increased levels of p-JNK1/2 when compared to the
irrelevant control siRNA (Figure 4B, lane 2 vs. 1 and lane 4 vs. 3, again statistical significance was
tightly missed in three independent experiments). These results suggest that TRAIL-R1 might not only
inhibit Smad but also non-Smad, for example, JNK signalling secondary to inhibition of TGFβ-RII.
2.5. MiR-370-3p Reduces TGFβ-induced Expression of PAI-1 and SLUG
Above, we have shown that miR-370 controls the expression of TGFβ-RII in a negative fashion.
To examine whether alterations in miR-370 levels affect the expression of established TGFβ target
genes, we transfected Panc1 cells with the miR-370-3p mimic, or control miR and subsequently treated
the cells with rec. TGFβ1 for 24 or 72 h. Interestingly, we noted a lower sensitivity of SERPINE1
(encoding plasminogen activator-inhibitor 1, PAI-1) and SNAI2 (encodi g SNAIL2/SLUG) to TGFβ1
stimulation as measured by qPCR (Figure 5).
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th  upper ban  represents Smad2. The blots in (A,B) are representative of three independent 
experiments all yielding, albeit to a varyi  extent, an induction of p-Smad2C and p-JNK levels, 
respectively, in TRAIL-R1-siRNA o r ctrl.-siRNA transfecte  cells. (C) Densitometry-bas d 
quantification of the p-Smad2 b nds shown in (A). (D) Densitometry-b sed quantification of the p-
JNK bands shown in (B).  
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SLUG. Panc1 cells were transiently transfected with 50 nM of control (ctrl) miR or a miR-370-3p mimic 
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Figure 5. Transfection with a miR-370-3p mimic decreases TGFβ1-induced expression of PAI-1 and
SLUG. Panc1 cells were transiently transfected with 50 nM of control (ctrl) miR or a miR-370-3p mimic
and 48 h later remained unstimulated (0) or were stimulated with TGFβ1 (5 ng/mL) for 24 or 72 h
(PAI-1), or 24 h (SLUG). Cells were examined for PAI-1- and SLUG- expression by qPCR. Data represent
the mean ± SD of three independent experiments (n = 3). The asterisks (*) indicate significance relative
to control (p < 0.05).
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2.6. MiR-370 Reduces TGFβ-induced Growth Inhibition
In order to test whether miR-370 can also affect more complex cellular responses to TGFβ,
for example, growth inhibition, we again transfected Panc1 cells with the miR-370-3p mimic, or control
miR and subsequently treated the cells with rec. TGFβ1 for 72 h. Intriguingly, the percentage of
viable cells in TGFβ1-treated cultures relative to non-treated control cultures was higher in cultures
that had been transfected with the miR-370-3p relative to ctrl.-miR transfected cells (Figure 6).
These data clearly show that miR-370-3p by downregulating TGFβ-RII not only suppresses the TGFβ
response of individual genes but also impacts growth arrest, a hallmark feature of TGFβ’s tumour
suppressor function.
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Figure 6. Transfection with a miR- 70-3p mimic decreases TGFβ1-induced growth i hibition.
Panc1 cells wer transiently transfected twice on two cons cutive days with 50 nM of control (ctrl) miR
or a miR-370-3p mimic and 24 h after the second r und of transfection r mai ed unstimulated (0) or
were stimulated with TGFβ1 (5 ng/mL) for 72 h. Following TGFβ1 stimulation, c lls w re d tached
and viable cells counted. Data represent the mean ± SD of three independent experiments (n = 3).
The number of non-TGFβ1-treated control cells were set arbitrarily at 100%. The asterisk (*) indicates
significance (p < 0.05).
2.7. Knockdown of TRAIL-R1 Enhances TGFβ-Induced PAI-1 Expression
Above, we have shown that ectopic expression of miR-370-3p decreased TGFβ1-induced PAI-1
expression (see Figure 5). Since miR-370, in turn, is positively controlled by TRAIL-R1 (see Figure 1),
we hypothesized that knockdown of TRAIL-R1 increases the sensitivity of SERPINE1 to TGFβ1
stimulation as a result of a concomitant decrease in miR-370 levels. To this end, Colo357 cells stably
expressing a TRAIL-R1 shRNA (Colo357-shTRAIL-R1) exhibited higher levels of PAI-1 after TGFβ1
stimulation (Figure 7).
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Figure 7. Knockdown of TRAIL-R1 in Colo357 cells enhances TGFβ1-mediated induction of PAI-1
expression. Colo357 cells stably transduced with a TRAIL-R1 shRNA, or control (ctrl.) shRNA remained
unstimulated (0) or were stimulated with TGFβ1 (5 ng/mL) for 24 h. Cells were assayed for PAI-1
mRNA expression by qPCR. Data represent the mean ± SD of three independent experiments (n = 3).
The asterisk (*) indicates significance relative to control (p < 0.05).
2.8. Ectopic Expression of a miR-370-3p Mimic Partially Reverses the TRAIL-R1 shRNA-induced TGFβ
Hyperstimulation of PAI-1 Expression
If TRAIL-R1 inhibits TGFβ1-dependent PAI-1 expression through miR-370-3p-mediated
down-regulation of TGFβ-RII, then the enhancement of the TGFβ1 effect on PAI-1 expression
following TRAIL-R1 depletion (see Figure 7) should be rescued by transfection of a miR-370-3p mimic.
To this end, transfection of Colo357-shTRAIL-R1 cells with miR-370-3p mimic partially reversed the
TGFβ1-induced hyperstimulation of PAI-1 expression when compared to a control miR (Figure 8).
Together with the results shown in Figure 7, these data confirm the functional link between miR-370-3p,
TRAIL-R1 and sensitivity to TGFβ being largely t r i ression of TGFβ-RII.
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Figure 8. Ectopic expression of a miR-370-3p mimic partially rescues Colo357 cells from the TRAIL-R1
shRNA-induced TGFβ1 hyperstimulation of PAI-1 expression. Colo357 cells with stable expression
of a TRAIL-R1 shRNA were transiently transfected with 50 nM of control (ctrl.) miR or a miR-370-3p
mimic and 48 h later stimulated with TGFβ1 (5 ng/mL) for 24 h. Data represent the mean±SD of three
independent experiments (n = 3). The asterisk (*) indicates significance relative to control (p < 0.05).
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3. Discussion
The role of miR-370-3p in malignant cells seems to vary depending on the tumour entity. Whereas
some studies found a tumour-promoting function, others conclude that miR-370-3p works as a tumour
suppressor [45–47]. According to the latter scenario, levels of miR-370 in gastrointestinal stromal
tumours, bladder carcinomas and neuroblastomas were reported to be low [48–50]. As shown by Xu
and co-workers, amounts of mature miR-370-3p declined during the development from pre-malignant
liver lesions to end-stage HCC [47]. Furthermore, these authors demonstrated that inhibition of
miR-370 resulted in a larger tumour mass, increased invasive potential and higher tumour stage.
Moreover, in tissue samples from patients, low levels of miR-370 correlated with reduced survival [47].
Previous studies indicated that miR-370-3p negatively controls expression of TGFβ-RII in gastric
carcinoma cells [45], however, equivalent data for PDAC cells are not available. High levels of
miR-370-3p would therefore be expected to be associated with lower levels of TGFβ-RII and presumably
attenuated TGFβ signalling activity and target gene expression. In agreement with this assumption
we found that transfection of cells with a miR-370-3p mimic reduced the sensitivity of SERPINE1 and
SNAI2 to TGFβ1 stimulation (see Figure 5) and partially relieved TGFβ1-induced growth arrest (see
Figure 6).
Little is known on the mechanisms that control mature miR-370 expression. In addition to their
well-known function as membrane-bound death-inducing receptors, TRAIL-R1 and -2 were also
found to localize in the nuclei of malignant cells [19]. Recently, it was uncovered that TRAIL-R2,
by associating with the nuclear proteins p68, NF45 and hnRNPA1, negatively regulated the maturation
of miR let-7, while expression of let-7 target proteins were elevated resulting in a more malignant
phenotype [20]. Here, we report that TRAIL-R1, too, engages in modulating miR expression since
knockdown of this receptor was accompanied by downregulation of miR-370-3p representing a novel
mechanism of positive regulation of miR-370 by TRAIL-R1. The observation that TRAIL-R1 but not
treatment of the cells with exogenous TRAIL, impact the expression of miR-370-3p argues in favour of
a ligand independent function of TRAIL-R1. Interestingly, however, antibody-mediated deprivation of
endogenous TRAIL slightly reduced miR-370-3p levels, the reason of which is not clear at present.
Given the negative association of miR-370 with TGFβ-RII expression on the one hand and its
positive association with TRAIL-R1 expression on the other hand, we hypothesized that TRAIL-R1 via
modulation of miR-370 should also affect the expression of TGFβ-RII in PDAC cells. Regulation of
TGFβ-RII via TRAIL/TRAIL-R system has not been described so far. As predicted, we observed that
TRAIL-R1 negatively regulates abundance of TGFβ-RII. We assume that the extra TGFβ-RII protein
that appears after TRAIL-R1 knockdown, is cell surface-associated as the TGFβ receptor complex
which is central to the regulation of TGFβ signalling is localized at the plasma membrane. This is
in line with the changes seen in the sensitivity of cells to TGFβ stimulation with respect to gene
expression and growth inhibition. We also analysed whether stimulation of PDAC cells with TRAIL
would affect expression of TGFβ-RII, however, TRAIL-R1 appears to function independently of its
ligand TRAIL here.
To gain further insight into a possible functional relevance of TGFβ-RII upregulation upon
TRAIL-R1 knockdown for the activation of TGFβ signalling, analysis of the canonical Smad signalling
pathway revealed a tendency towards an activation after stimulation with TGFβ1. The same tendency
was noted for non-Smad TGFβ signalling pathways, for example, JNK1/2, which appeared to be
activated after TRAIL-R1 knockdown under both non-stimulated and TGF β1-stimulated conditions.
An attempt to quantify the increase in p-Smad2C and p-JNK levels in TRAIL-R1-depleted cells from
three experiments, however, yielded p-values slightly greater than 0.05. We are currently performing
additional experiments to increase the probability that differences become statistically significant.
In addition, we are monitoring activation of Smad3 to further support inhibition of canonical Smad
signalling by TRAIL-R1. A possible increase in JNK activation following TRAIL-R1 knockdown
independent of TGFβ1 stimulation (see Figure 4, lane 1 vs. 2) may be due to the binding of endogenous
TRAIL to TRAIL-R2. This explanation is supported by the fact that TRAIL-R2 but not TRAIL-R1 signals
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through JNK activation [51]. Finally, we show that TRAIL-R1 knockdown-induced upregulation of
TGFβ-RII led to a dramatic increase in the expression of the (Smad-dependent) TGFβ target gene
SERPINE1 in Colo357 cells (see Figure 7). Intriguingly, this effect could be partially blocked by transient
transfection of the cells with the miR-370-3p mimic (see Figure 8).
Recently, we have uncovered an interdependence of TGFβ and TRAIL-induced signalling in
PDAC cells. We found that TGFβ1 decreased the levels of TRAIL-R1 and negatively impacted
TRAIL-R1-mediated apoptosis and non-apoptotic signalling [52]. Together, our previous and current
data create interesting scenarios depending on the level of expression of TGFβ. Since PDAC cells show
high expression levels of TRAIL-R1 [19,20], which positively controls miR-370 expression, we propose
that miR-370 is abundant in early-stage PDAC when TGFβ is low. In this miR-370-rich environment,
mRNA transcribed from TGFBR2 will be degraded and, hence, TGFβ signalling and TGFβ-driven
tumourigenesis inhibited. In line with this assumption, high levels of cytoplasmic TRAIL-R1 expression
in tumour cells have been shown to correlate with better prognosis of patients with PDAC [53] and
other tumour entities (reviewed in Ref. 19).
In contrast, in later stages of PDAC when TGFβ1 levels are high in tumours, this scenario will
change dramatically. TGFβ1 is then expected—via inhibiting TRAIL-R1 [52]—to downregulate also
miR-370. Interestingly, the fraction of pancreatic cancer samples with positive membrane staining for
TRAIL-R1 was found to be lower than that of cells from surrounding non-tumour tissues [54]. Likewise,
miR-370 expression, too, is underexpressed in both pancreatic cancer precursor lesions [37] and cancer
cells [55] compared to normal healthy tissue and cells, respectively. A more direct link between
TGFβ and miR-370-3p recently came from an ovarian cancer cell model [56]. Here, TGFβ treatment
downregulated miR-370-3p and a miR-370-3p knockdown or miR-370-3p overexpression promoted or
suppressed, respectively, TGFβ-induced epithelial-mesenchymal transition [56] the latter process of
which is considered a crucial event in TGFβ’s protumourigenic function. Downregulation of miR-370
may relieve TGFβ-RII expression from inhibition and eventually further stimulate TGFβ expression [57]
resulting in hyperactivation of TGFβ signalling. This vicious cycle of TGFβ signalling [57] may be
responsible for driving aggressive behaviour, invasive potential and metastasis in late-stage PDAC
and other gastrointestinal stroma-rich tumours.
4. Conclusions
In summary, we present here a novel mechanism of TRAIL-R1-dependent, miR-370-mediated
regulation of the expression of TGFβ-RII that finally resulted in corresponding alterations in
TGFβ-dependent target gene expression and growth inhibition. Many miRs were found to be
deregulated in PDAC cells correlating with worsened patient outcome, chemoresistance and invasive
behaviour [58]. Although selective modulation of miRs is still not trivial [59], pharmacological
intervention to decrease or increase distinct miRs to improve therapy outcomes in patients with
pancreatic carcinomas is nevertheless a promising strategy. Eventually, miR-370 may emerge as
a promising candidate among other TGFβ signalling inhibitors that are currently evaluated in
anticancer therapy [60–62].
5. Materials and Methods
5.1. Culture Conditions, Cell Stimulation and Counting
The human pancreatic cancer cell lines Panc1 and Colo357 were cultured in RPMI 1640 media
supplemented with 10% FCS, 1 mM GlutaMAX and 1 mM sodium pyruvate (Life Technologies,
Darmstadt, Germany). For selection of stably retrovirally transduced Colo357 cells the antibiotic
puromycin was added to the culture media (2.5 µg/mL). Cells were grown for 24 h in six-well-plates
before transfection and/or stimulation. Cell-stimulating agents used were TGFβ1 (ReliaTech,
Wolfenbüttel, Germany), recombinant human TRAIL (10 ng/mL; PeproTech, Hamburg, Germany) and
neutralizing TRAIL antibody (anti-TRAIL) (10 µg/mL; R&D Systems). For cell counting, cells were
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detached by trypsinization and viable cells (as determined by trypan blue exclusion) counted in
a Neubauer chamber.
5.2. Transfection of siRNA, shRNA and miR-370
1.7 × 105 cells were seeded in six-well-plates the day before transfection. Control siRNA and siRNA
against TRAIL-R1 were used in a concentration of 2 nM, both of them purchased from GE Healthcare
(ON-TARGETplus® SMARTpool non-targeting pool D-001810-10, L-008090-00; GE Healthcare, Freiburg,
Germany). To obtain cells with a stable knockdown of TRAIL-R1, Colo357 cells were transduced with GIPZ
lentiviral shRNAmir vectors for TRAIL-R1 or with a non-silencing control (Open Biosystems; CloneID:
V3LHS_383714). MirVana® miR mimic hsa-miR-370-3p and the respective control were purchased
from Ambion, Life Technologies, Darmstadt, Germany. DharmaFECT®1 (Thermo Scientific, Schwerte,
Germany) or Lipofectamin 2000 (Life Technologies/ThermoFisher Scientific, Darmstadt, Germany served
as transfection reagents and were used according to the manufacturers’ instructions. Forty-eight h after
transfection, cells were stimulated with the aforementioned factors and then subjected to protein extraction
or RNA isolation.
5.3. Western Blot Analysis
For extraction of proteins, cells were lysed in RIPA buffer including a protease- (cOmplete
Mini, Roche Diagnostics) and a phosphatase inhibitor (PhosSTOP, Roche Diagnostics). Performance
of Western blot analysis was described before [63]. Primary antibodies were purchased from Cell
Signalling, Frankfurt, Germany (anti-JNK, anti-phospho-JNK, anti-phospho-Smad2); Merck Millipore,
Darmstadt, Germany (anti-TRAIL-R1); Santa Cruz Biotechnology, Dallas, TX, USA (anti-TGFβ-RII,
anti-Smad2/3); Sigma-Aldrich, St. Louis, MO, USA (β-actin).
5.4. RNA Isolation, Reverse Transcription and Polymerase Chain Reaction
RNA was extracted from cells by a mirVanaTM miR kit (Ambion). Quantitative real time PCR of the
complementary DNA (TaqMan, Applied Biosystems, Foster City, CA, USA) was performed on a 7900HT
Fast Real-Time PCR system (Applied Biosystems) using TaqMan qPCR Master Mix (ThermoFisher
Scientific Dharmacon, Epsom, UK) and MIR370 TaqMan MicroRNA Assay (ThermoFisher Scientific,
Cat.-# 4427975) pri-miR-370 Assay (ThermoFisher Scientific, Hs03303493_pri), RNU6B Assay
(ThermoFisher Scientific) or GAPDH Assay (ThermoFisher Scientific, Hs99999905_m1). Other primers
used were: PAI-1 (forward: cttcttcaggctgttccggagc; reverse: gggtcagggttccatcacttgg), Slug (forward:
atattcggacccacacattacct; reverse: gcaaatgctctgttgcagtga) and TATA box-binding protein (TBP, forward:
gctggcccatagtgatcttt; reverse: cttcacacgccaagaaacag). The latter two housekeeping genes were amplified
as controls. For quantification, the delta-delta Ct method was employed to show expression levels of
the genes-of-interest after normalization with RNU6B (for mature miR-370), GAPDH (for pri-miR-370)
or TBP (for PAI-1 and SLUG).
5.5. Statistical Analysis
All data were normally distributed and analysed using two-tailed student’s t-test. A p value < 0.05
was considered statistically significant. Data are shown as mean ± standard deviation (SD). Statistical
analysis was performed using Sigma Plot 12.5 software (Systat Software, Erkrath, Germany).
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/11/399/
s1. Figure S1: TRAIL-R1 regulates the expression of miRs; Figure S2: TRAIL-R2 knockdown has no effect on
miR-370-3p expression in Panc1 cells; Figure S3: TRAIL-R1 knockdown elevates protein levels of TGFβ-RII in
Colo357 cells.
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